Tuesday 18th June 2013 |
Text too small? |
Mylan New Zealand, the local unit of the world’s third-largest generic-drug maker, boosted profit by two-thirds last year as sales growth outpaced expenses.
Profit rose 62 percent to $9.4 million in the 12 months ended Dec. 31, the Auckland-based company said in accounts filed with the Companies Office. Revenue jumped 18 percent to $54.7 million while the cost of sales advanced 10 percent to $35.6 million, according to the company accounts.
Mylan New Zealand managing director Lloyd Price declined to comment on the accounts. The local unit is one of New Zealand’s largest pharmaceutical companies and specialises in generic lines, according to its website.
Canonsburg, Pennsylvania-based Mylan increased total revenue 11 percent to US$6.8 billion in 2012 and said sales may rise by as much as 9 percent this year. Sales have been boosted in recent years as lacklustre economic growth spurred demand for lower-cost health options including generic versions of drugs.
The New Zealand unit benefited from a $147,000 foreign exchange gain last year, compared with a $123,000 loss in 2011, the accounts show. The New Zealand dollar appreciated about 6.3 percent over the year against the US dollar.
Mylan ranks behind Novartis’s generic arm Sandoz and Teva Pharmaceuticals Industries in global sales of generic drugs. The company’s Nasdaq-listed shares have gained 15 percent this year, valuing Mylan at US$12.02 billion.
BusinessDesk.co.nz
No comments yet
SPG - Change to Executive Team
BGI - Forgiveness of $200,000 of secured indebtedness
General Capital Subsidiary General Finance Market Update
AFT,Massey Ventures,Gilles McIndoe to develop scar treatmen
April 24th Morning Report
Cheers to many fewer grape harvest spills
GTK - Half-Year Results Announcement Date
Government ends war on farming
Sky and BBC Studios renew expanded, multi-year agreement
AOF - Q1 Improved Trading Performance & FY24 Guidance Maintained